Legal Representation
Attorney
Jonathan M. Rixen
USPTO Deadlines
Next Deadline
1941 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20250415)
Due Date
April 15, 2031
Grace Period Ends
October 15, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 15, 2025 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Apr 15, 2025 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Mar 24, 2025 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Mar 24, 2025 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Mar 21, 2025 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jan 16, 2025 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 21, 2025 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jan 14, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Jan 14, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 14, 2025 | EWOR | I | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | Loading... |
| Jan 14, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jan 14, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jan 16, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Oct 8, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 13, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 13, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 24, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 9, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 17, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 1, 2024 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| May 1, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 10, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Active pharmaceutical ingredients (APIs), namely, oligonucleotide APIs for use in the manufacture of pharmaceuticals for treating tumor, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; active chemical ingredients for use in the manufacture of pharmaceuticals for treating tumor, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia
First Use Anywhere:
Mar 16, 2021
First Use in Commerce:
May 7, 2023
Additional Information
Design Mark
The mark consists of a horizontal figure 8 with a pointed design protruding from the upper left corner, and four interwoven short lines inside an oval in the right.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
EIGHT
Classification
International Classes
001